logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Safety and effectiveness of short-course AmBisome in the treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a prospective cohort study in Bangladesh | Journal Article / Research | MSF Science Portal
Journal Article
|Research

Safety and effectiveness of short-course AmBisome in the treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a prospective cohort study in Bangladesh

den Boer ML, Das AK, Akhter F, Burza S, Ramesh V, Ahmed BN, Zijlstra EE, Ritmeijer KKD
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
A safe and effective short-course treatment regimen for Post Kala Azar Dermal Leishmaniasis (PKDL) is considered essential for achieving and sustaining elimination of visceral leishmaniasis (VL) in the Indian subcontinent.(1, 2) Here, single dose liposomal amphotericin B (AmBisome) has been adopted as a first line regimen for VL; however the effectiveness and safety of AmBisome for PKDL has not been formally evaluated.

Countries

Bangladesh

Subject Area

neglected tropical diseaseskala azar

Languages

English
DOI
10.1093/cid/ciy172
Published Date
15 Mar 2018
PubMed ID
29554244
Journal
Clinical Infectious Diseases
Volume | Issue | Pages
Volume 67, Issue 5
Issue Date
2018-03-15
Dimensions Badge